Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.

1. Role of m5C methylation in digestive system tumors (Review).Molecular medicine reports · 2025
   Pooled it
2. Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026
   Review
3. ICIsAtlas reveals a suppressive NK cell niche in pan-cancer immunotherapy profiles.Communications biology · 2026
   Article
4. The ZIF-8 nanoplatform targeted delivery of IFI44 siRNA to suppress bladder cancer development via modulating the PI3K/AKT signaling pathway.Journal of nanobiotechnology · 2026
   Article
5. Epigenetic modifications in cancer drug resistance: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026
   Review
6. Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.Cell reports. Medicine · 2026
   Article
7. Comparative Preclinical Evaluation of BIX-01294 and UNC0642 as EHMT2-Targeting Anticancer Agents.Cancers · 2026
   Article
8. Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.Journal of experimental & clinical cancer research : CR · 2026
   Article
9. 5-mC RNA methylation: a key regulator in cancer development and treatment.Journal of translational medicine · 2026
   Review
10. Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-β1 suppression.EMBO molecular medicine · 2026
    Article
11. Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies.Frontiers in oncology · 2026
    Review
12. m5C RNA methylation in cancer: from biological mechanism to clinical perspectives.European journal of medical research · 2025
    Review
13. Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors.Molecular cancer · 2025
    Article
14. Death-ision: the link between cellular resilience and cancer resistance to treatments.Molecular cancer · 2025
    Review
15. G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials.Medicinal research reviews · 2025
    Review
16. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2025
    Article
17. CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.Frontiers in immunology · 2025
    Review
18. The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies.Frontiers in oncology · 2025
    Review
19. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.Cell death & disease · 2024
    Article
20. Suppression of double-stranded RNA sensing in cancer: molecular mechanisms and therapeutic potential.Biochemical Society transactions · 2024
    Review

62 more citing papers are in PubMed but not listed here.

Corrections and comments

• Commented on by
  Combining epigenetic and immune checkpoint inhibitors in bladder cancer.2019
• Commented on by
  Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway.2019
• Commented on by
  Novel G9a/DNMT first-in-class dual reversible inhibitor has potent antitumor effect in bladder cancer.2020
• Commented on by
  Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression.2020

Authors and funding

28 authors at 6 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as